Endocrine Abstracts

Introduction and Objectives: Continuous glucose monitoring (CGM) has demonstrated benefits in the prevention of hypoglycemia in patients with type 1 diabetes mellitus (DM1) vs flash monitoring (CGM). Our aim was to analyze the clinical characteristics, indication and glucometric changes in patients using MFG after CGM implantation.

Material and methods: Retrospective observational study of 13 patients under follow-up for DM1 in Endocrinology consultations at the Hospital Universitario Clínico San Cecilio with suboptimal glycemic control using MFG who underwent implantation of MG (Dexcom G6). Demographic variables related to the disease and its complications and glucose monitoring parameters before and after implantation of the Dexcom G6 system were studied.

Results: 7 women and 6 men were evaluated. Mean age 40±14.1 years, mean time of diabetes evolution 16.9±11.1 years. Mean BMI 24.7±3.27. 2 kg/m². Only 2 patients had microangiopathic complications. The mean time of use of MFG was 2.5 years and of MG 7.8 months. In 12 patients, the indication for CGM was frequent hypoglycemia, the remaining case being due to skin reaction. After the indication for CGM, HbA1c (6.9 vs 6.4%, P=0.039), time below range (7.4 vs 2.5, P=0.001) and coefficient of variation (37.5 vs 32.8, P=0.004) decreased significantly. There were no significant changes in time in range or time in hyperglycemia.

Conclusions: In our study, the use of GCM compared to previous MFG use is related to better glycemic control in patients with DM1 in terms of HbA1c, with reduced time in hypoglycemia and coefficient of variation. GCM systems may be useful in the management of the DM1 patient with a tendency to hypoglycemia and wide glycemic variability.